Stephanie L. Foster
YOU?
Author Swipe
View article: Patient and public involvement in the SPRUCE methodology study investigating electronic patient reported outcomes in oncology clinical trials
Patient and public involvement in the SPRUCE methodology study investigating electronic patient reported outcomes in oncology clinical trials Open
Background Patient reported outcomes (PRO) provide crucial insight into trial participants’ experience of oncology treatments. At the Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU), these are completed b…
View article: Endogenous regulator of G protein signaling 14 (RGS14) blunts cocaine-induced emotionally motivated behaviors in female mice
Endogenous regulator of G protein signaling 14 (RGS14) blunts cocaine-induced emotionally motivated behaviors in female mice Open
Addictive drugs hijack the neuronal mechanisms of learning and memory in motivation and emotion processing circuits to reinforce their own use. Regulator of G-protein Signaling 14 (RGS14) is a natural suppressor of post-synaptic plasticity…
View article: The Agency Obligation to Explain Redactions
The Agency Obligation to Explain Redactions Open
View article: Examining Unusual Patterns of Cancer and Environmental Concerns: The Importance of Community Input and Engagement
Examining Unusual Patterns of Cancer and Environmental Concerns: The Importance of Community Input and Engagement Open
Context: In fiscal year 2019, the Department of Health and Human Services (DHHS) received an appropriation from Congress specifically to update guidelines for investigating community cancer concerns. This resulted in the DHHS directing the…
View article: Eosinophils protect against SARS-CoV-2 following a vaccine breakthrough infection
Eosinophils protect against SARS-CoV-2 following a vaccine breakthrough infection Open
Waning immunity and the emergence of immune evasive SARS-CoV-2 variants jeopardize vaccine efficacy leading to breakthrough infections. We have previously shown that innate immune cells play a critical role in controlling SARS-CoV-2. To in…
View article: Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference study
Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference study Open
Introduction Patient-reported outcomes (PRO) are currently collected from trial participants using paper questionnaires by the Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU). Streamlining PRO collection …
View article: Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence Between Angola and Ci67 Strains
Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence Between Angola and Ci67 Strains Open
Background Marburg virus (MARV) has caused numerous sporadic outbreaks of severe hemorrhagic fever in humans. Human case fatality rates of Marburg virus disease (MVD) outbreaks range from 20% to 90%. Viral genotypes of MARV can differ by o…
View article: Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants Open
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a s…
View article: Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials Open
View article: Guidelines for examining unusual patterns of cancer and environmental concerns
Guidelines for examining unusual patterns of cancer and environmental concerns Open
The Centers for Disease Control and Prevention (CDC) National Center for Environmental Health (NCEH) and the Agency for Toxic Substances and Disease Registry (ATSDR) provide scientific guidance to state, tribal, local, and territorial (STL…
View article: Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease
Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease Open
The emergence of the novel henipavirus, Langya virus, received global attention after the virus sickened over three dozen people in China. There is heightened concern that henipaviruses, as respiratory pathogens, could spark another pandem…
View article: Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant Open
PURPOSE To examine COVID-19 mRNA vaccine–induced binding and neutralizing antibody responses in patients with non–small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose an…
View article: Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant Open
View article: Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer Open
Background Platform trial designs are used increasingly in cancer clinical research and are considered an efficient model for evaluating multiple compounds within a single disease or disease subtype. However, these trial designs can be cha…
View article: Implementing electronic patient reported outcome data capture for multi-centre oncology clinical trials
Implementing electronic patient reported outcome data capture for multi-centre oncology clinical trials Open
Background: Traditionally patient reported outcomes (PRO) are collected on paper as key endpoints for clinical trials. With increasing internet usage there is an interest in the use of electronic patient reported outcomes. Although previou…
View article: mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron Open
View article: A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease Open
Significance Concern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While…
View article: mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron Open
Summary SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-specific vaccines would …
View article: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant Open
View article: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters Open
View article: Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler
Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler Open
We describe rapid detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant using targeted spike single-nucleotide polymorphism polymerase chain reaction and viral genome sequencing. This case occurred i…
View article: Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern Open
Purpose We investigated SARS-CoV-2 mRNA vaccine-induced binding and live-virus neutralizing antibody response in NSCLC patients to the SARS-CoV-2 wild type strain and the emerging Delta and Omicron variants. Methods 82 NSCLC patients and 5…
View article: The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters
The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters Open
Despite the development and deployment of antibody and vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein jeopardize their efficacy. The recent emergence of B.1.1.529, …
View article: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant Open
The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutatio…
View article: Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization Open
The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum s…
View article: Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR
Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR Open
An immunoassay that targets the nonstructural secreted glycoprotein decoy antigen of Ebola virus detects infection earlier than PCR.
View article: Establishment of an African green monkey model for COVID-19 and protection against re-infection
Establishment of an African green monkey model for COVID-19 and protection against re-infection Open
View article: Establishment of an African green monkey model for COVID-19
Establishment of an African green monkey model for COVID-19 Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to screen candidate vaccines and trea…
View article: Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model
Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model Open
View article: An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys
An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys Open
Due to the difficulty in conducting clinical trials for vaccines and treatments against Nipah virus (NiV), licensure will likely require animal models, most importantly non-human primates (NHPs). The NHP models of infection have primarily …